HPV testing and vaccination in Europe

Journal of Lower Genital Tract Disease

Volumn 18, Issue 1, 2014, Pages 61-69

  Leeson, Simon C ^a   Alibegashvili, Tamar ^b   Arbyn, Marc ^c   Bergeron, Christine ^d   Carriero, Carmine ^e   Mergui, Jean Luc ^f   Nieminen, Pekka ^g   Prendiville, Walter ^h   Redman, Charles W E ⁱ   Rieck, Gudrun C ^a   Quaas, Jens ^j   Petry, K Ulrich ^k  

^a BETSI CADWALADR UNIVERSITY HEALTH BOARD   (United Kingdom)

^b National Screening Center   (Georgia)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^d LABORATOIRE CERBA   (France)

^e UNIVERSITY OF BARI   (Italy)

^f HÔPITAL TENON   (France)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h Beacon Hospital   (Ireland)

ⁱ UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^j Klinikum Wolfsburg ^*  (Germany)

^k Klinikum Wolfsburg   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EARLY DETECTION OF CANCER; EUROPE; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84894034916     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0b013e318286b8d3     Document Type: Article

References (55)

1. Arbyn M, Autier P, Ferlay J. Burden of cervical cancer in the 27member states of the European Union: Estimates for 2004. Ann Oncol 2007;18:1423-5.
2. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical mortality in the member states of the European Union. Eur J Cancer 2009;45:2640-8.
3. ECCA. Available at: Http://www.ecca.info/en/cervicalcancer-prevention/ cervical-screening/cse1/table-2.html. 2009. Accessed April 16, 2012.
4. Arbyn M, Weiderpass E, Capocaccia R. Effect of screening on deaths from cervical cancer in Sweden. BMJ 2012; 344:11.
5. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-86.
6. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med 2003;348:518-27.
7. KitchenerHC, AlmonteM,Wheeler P, DesaiM,Gilham C, Bailey A, et al.HPVtesting in routine cervical screening: Cross sectional data from the ARTISTIC trial. Br J Cancer 2006;95: 56-61.
8. Howell-Jones R, Bailey A, Beddows S, Sargent A, de Silva N, Wilson G, et al. Multi-site study of HPV typeYspecific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer 2010; 103:209-16.
9. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A metaanalysis update. Int J Cancer 2007;121:621-32.
10. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:100-10.
11. Lehtinen M, Paavonen J, Wheeler CM, Jaisamram U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89-99.
12. Goldie SJ. Public health policy and cost-effectiveness analysis. Chapter. J Natl Cancer InstMonogr 2003;31:102-10.
13. David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, et al. Long-term persistence of anti-HPV-16 and-18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol 2009;115(suppl):S1-6.
14. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: A randomised controlled trial. Lancet Oncol 2010;11:249-57.
15. Cuzick J, Castanon A, Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br J Cancer 2010;102:933-9.
16. Collins Y, Einstein MH, Gostout BS, Herzog TJ, Massad LS, Rader JS, et al. Cervical cancer prevention in the era of prophylactic vaccines: A preview for gynecologic oncologists. Gynecol Oncol 2006;102:552-62.
17. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomized clinical trials. Lancet 2007;369:1693-702.
18. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Clinical applications of HPV testing: A summary of meta-analyses. Ch. Vaccine 2006;24(suppl 3):S78-89.
19. Guido R, Schiffman M, Soloman D, Burke L. Postcolposcopy management strategies for patients referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous lesions of undetermined significance: A two-year prospective study. Am JObsterGynecol 2003;188:1401-5.
20. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomised trial on the management of cytologic interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383-92.
21. ASCUS-LSILTriage Study (ALTS) Group. A randomised trial on the management of low grade squamous intraepithelial lesion cytologic interpretations. Am J Obstet Gynecol 2003; 188:1393-400.
22. Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M, Ogilvie G, et al. Evidence regardingHPVtesting in secondary prevention of cervical cancer. Vaccine 2012;(30 suppl 5):88-99.
23. Kelly RS, Patnick J, Kitchener HC, Moss SM. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: Results from the Sentinel Sites study. Br J Cancer 2011;105:983-8.
24. Spinillo A, Dal Bello B, Gardella B, Roccio M, Dacco MD, Silini EM. Multiple human papillomavirus infection and high grade cervical intraepithelial neoplasia among women with cytological diagnosis of atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions. Gynecol Oncol 2009;113:115-9.
25. Stoler MH,Wright TC, Sharma A, AppleR,GutekunstK, Wright TL. High-risk human papillomavirus testing in women with ASC-US cytology. Results from the ATHENA HPV study. Am J Clin Pathol 2011;135:468-75.
26. Wheeler CM, Hunt WC, Schiffman M, Castle PE. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis 2006;194:1291-9.
27. Kelly RS,Walker P, Kitchener H, Moss SM. Incidence of cervical intraepithelial neoplasia grade 2 orworse in colposcopynegative/human papillomavirusYpositive women with lowgrade cytological abnormalities. BJOG 2012;119:20-5.
28. Denton KJ, Bergeron C, Klement P, Trunk MJ, Keller T, Ridder R. The sensitivity and specificity of p16INK4a cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results. Am J Clin Pathol 2010;134:12-21.
29. Schmidt D, Bergeron C, Denton KJ, Ridder R. p16/Ki-67 dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology. Cancer Cytopath 2011;119:158-66.
30. Chan BKS, Melnikow J, Slee CA, Arellanes R, Sawaya GF. Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: A systematic review. Am J Obstet Gynecol 2009;200:422.e1-9.
31. Kitchener HC, Walker PG, Nelson L, Hadwin R, Patnick J, Anthony GB. HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG 2008;115:1001-7.
32. Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: A long-term multi-cohort study. Lancet Oncol 2011;12:441-50.
33. Coupé VM, Berkhof J, Verheijen RH, Meijer CJ. Costeffectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG 2007;114:416-24.
34. Flannelly G, Bolger B, Fawzi H, Fawzi H, De Lopez AB, Monaghan JM. Follow up after LLETZ: Could schedules be modified according to risk of recurrence BJOG 2001; 108:1025-30.
35. Costa S, Negri G, Sideri M, Santini D, Martinelli G, Venturoli S, et al. Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix. Gynecol Oncol 2007;106:170-6.
36. Moss EL, Pearmain P, Askew S, Owen G, Reynolds TM, Prabakar IM, et al. Implementing the national invasive cervical cancer audit: A local perspective. BJOG 2010;117: 1411-6.
37. Sasieni P, Castanon A, Louie KS. NHSCSP Audit of Invasive Cervical Cancer. National Report 2007-2010. Sheffield, UK: NHS Cancer Screening Programme; 2011.
38. Arbyn M, Ronco G, Meijer CJ, Naucler P. Trials comparing cytology with human papillomavirus screening. Lancet Oncol 2009;10:935-6.
39. Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P, Tarkkanen J, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: Randomised study within organised screening programme. BMJ 2010; 340:c1804.
40. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for 330,000 women undergoing concurrent HPV testing and cervical cytology in routine clinical practice at a large managed care organisation. Lancet Oncol 2011;12:663-72.
41. Arbyn M, de Sanjosé S, Saraiya M, Sideri M, Palefsky J, Lacey C, et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 2012;131: 1969-82.
42. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Eng J Med 2007;357: 1589-97.
43. Bulkmans N, Berkhof J, Rozendaal L, van Kamenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-72.
44. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): A randomised controlled trial. Lancet Oncol 2009;10:672-82.
45. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: A systematic review and meta-analysis of non-randomised studies. Gynecol Oncol 2007;104:232-46.
46. Cuzick J, Clavel C, Petry K-U, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-101.
47. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study. BMJ 2008;337:a1754.
48. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: Role of persistence. J Natl Cancer Inst 2010;102:1478-88.
49. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: A 10-year cohort analysis. J Natl Cancer Inst 2003;95:46-52.
50. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 of 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9.
51. Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, et al. ARTISTIC: A randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009;13:51.
52. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, et al. Cervical infection and neoplasia in a large populationbased prospective study: The Manchester cohort. Br J Cancer 2004;91:942-53.
53. Gok M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JW, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: Cohort study. BMJ 2010;340:c1040.
54. Jordan J, Martin-Hirsch P, Arbyn M, Schenk U, Baldauf JJ, Da Silva D, et al. European guidelines for quality assurance in cervical cancer screening: Recommendations for clinical management of abnormal cervical cytology, part. Cytopathology 2008;19:342-54.
55. Jordan J, Martin-Hirsch P, Arbyn M, Schenck U, Baldauf J-J, Da Silva D, et al. European guidelines for management of abnormal cervical cytology, part. Cytopathology 2009;20:5-16.